Genentech Issues Statement on Hemlibra

Genentech has released a statement to clarify the facts surrounding five people with hemophilia A with inhibitors to factor VIII who have passed away while receiving Hemlibra® (emicizumab-kxwh).

Read Genentech’s press release HERE.

If you have questions or concerns, please reach out to Genentech and/or your physician. Genentech has a Medical Communications line at (800) 821-8590 for patients, concerned community members, and healthcare providers who seek further information.




Leave a Reply

About Us

The Hemophilia Foundation of Michigan strives to improve the quality of life for all people affected by hemophilia, von Willebrand disease, other coagulation disorders, and related complications.

Recent Posts

It’s a Great Time to Review Your Insurance Plan for 2019

A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …

Read More →

What is an Accumulator Adjustment Program?

Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients using these cards.

Read More →

Follow Us

Sign up for our Newsletter

Get all the latest updates and news from  HFM

  • This field is for validation purposes and should be left unchanged.
Skip to content